Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-15
1997-05-13
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514557, 514625, A61K 31445, A61K 3116, A61K 3119
Patent
active
056293275
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
D'Amato et al., "Thalidomide is an inhibitor of angiogenesis," Proc. Natl. Acad. Sci., USA, vol. 91, pp. 4082-4085, 1994.
Belaube et al., "Faut-il rehabilitier la thalidomide,?" [Should Thalidomide be Rehabilitated?,] Sem. H op. Paris, 59(45):3101-3104 (Dec. 8, 1983); Medline, accession No. 84121350. Translation attached.
Waters, et al., "Treatment of Ulcerative Colitis with Thalidomide," British Medical Journal, p. 792 (Mar. 24, 1979).
Brem et al., J. Neurosurg., 74: pp. 441-446 (1991).
Crum et al., Science, 230:1375 et seq. (1985).
Taylor et al., Nature, 297:p. 307 (1982).
Folkman et al., Science, 221: p. 719 (1983).
Sidky et al., Cancer Res., 47: pp. 5155-5161 (1987).
White et al., New England J. Med., 320: pp. 1197-1200 (1989).
Eger, K. et al., Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide, Arzneim.-Forsch/Drug Res. 40 (II). Nr. 10 (1990), pp. 1073-1075.
Fabro, S. et al., Teratogenic Activity of Thalidomide and Related Compounds, Life Sciences vol. 3, pp. 987-992, 1964.
Eriksson, Sven O., Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides, Acta Pharm. Sucecica 10, pp. 63-74 (1973).
Fickentscher, K., Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides, Mol. Pharmacology 13, pp. 133-141. 1977.
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 521-542 (1972).
Matsuyama, Toshifumi, Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?, AIDS 1991, vol. 5 No. 12, pp. 1405-1417.
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 431-446 (1972).
Hendler, Sheldon S. et al., Thalidomide for Autoimmune Disease, Medical Hypotheses 10:pp. 437-443 (1983).
Jonsson, N. Ake, et al. Chemical Structure and Teratogenic Properties, Acta Pharm. Succica 9, pp. 543-562 (1972).
Cebulak Mary C.
Children's Hospital Medical Center Corp.
Dees Jos e G.
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1385650